Vija singh (2 risultati)

Perfeziona la tua ricerca

  • Libri (2)

a

Fascia di prezzo personalizzata (EUR)

a

    • Condizione: Usato - Molto buono

      EUR 166,15

      EUR 25,00 spedizione 
      Spedito da Sudafrica a U.S.A.

      Quantità: 1 disponibili

      Aggiungi al carrello

      Softcover. Condizione: Very Good. No Jacket. First Edition. February 1982. Bookplate on the first blank page. Signed by the previous owner on the front free end paper page and two stamp marks. Publication of 180 pages printed, only one side used. Large book. The wraps are a little shelf rubbed, small creases and a touch edge worn. Internally the pages are clean and complete. The text is legible. The binding is excellent. GK. Our orders are shipped using tracked courier delivery services.

    • Lingua: Inglese

      Editore: Elsevier Inc Jan 2025, 2025

      044322420X / 9780443224201

      • Rilegato

      Da: AHA-BUCH GmbH, Einbeck, GermaniaAHA-BUCH GmbH

      Venditore con 5 stelle
      Contatta il venditore

      Condizione: Nuovo

      EUR 372,71

      EUR 30,50 spedizione 
      Spedito da Germania a U.S.A.

      Quantità: 2 disponibili

      Buch. Condizione: Neu. Neuware - CRISPR-Cas-Based Genome Editing for Treating Human Diseases, Part B represents CRISPR-Cas systems for genome editing. Currently, CRISPR-Cas systems have been proven to be a key technology for targeted genome editing, which is acting as a simple, rapid, and cost-effective solution. Chapters in this release include Current approaches in CRISPR -Cas systems for metabolic disorders, Recent progress in CRISPR -Cas systems for CRISPR for retinal diseases, Recent progress in CRISPR -Cas systems for cataract and blindness, Advances in CRISPR -Cas systems for muscular dystrophy, Recent development in CRISPR -Cas systems for cardiac disease, Current approaches in CRISPR -Cas systems for diabetes, and much more.Additional sections cover Advances in CRISPR -Cas systems for liver disease, Advances in CRISPR -Cas systems for lung disease, Advances in CRISPR -Cas systems for kidney diseases, Current progress in CRISPR -Cas systems for rare disease, Advances in CRISPR -Cas systems for heredity disease, Recent progress in CRISPR -Cas systems for neurological disorders, and CRISPR challenges in clinical developments.